Drug Discovery World DDW public
[search 0]
More

Download the App!

show episodes
 
Here at Drug Discovery World (DDW) we've been publishing articles written by leading experts in the Drug Discovery, Pharmaceutical, and BioPharmaceutical industries for over 20 years. DDW has grown as a quarterly business review of drug discovery and development, and now we've created this podcast to allow you to listen to our articles on the go. In our journal and this podcast, we cover topics surrounding: drug discovery; drug development; business; chemistry; enabling technologies; informa ...
 
Loading …
show series
 
This is the latest episode of the free DDW podcast: “Opportunities to improve drug discovery systems”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine. The first article is titled “Precision control of protein release to reconfigure bioprocessing and cell-based assays”, where the authors D…
 
This is the latest episode of the free DDW podcast, “Putting virology back on the map: the fight against Covid-19”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine. The first article is a case study titled “New technology in COVID research may accelerate vaccines”, and the second is called…
 
John Couse, Vice President of Scientific Services at Taconic Biosciences discusses the benefits of a robust colony management solution/partner in the drug discovery success; how it can enable companies to scale through resource management and create efficiencies. Couse has extensive knowledge of colony managements solutions and outlines the benefit…
 
In this podcast Dr. Joanna Hawryluk discusses automating the cell culture workflow and explains the importance of cell culture workflow in the drug discovery process and how it can be improved thanks to technological advances. Hawryluk talks us through the cell culture workflow and its relevance within the drug discovery process focussing on the ar…
 
This episode covers two narrated articles written for DDW and is read aloud by Megan Thomas, both of which were published in Volume 22, Issue 1 – Winter 2020/21 of Drug Discovery World. The first article is titled, “Streamlining gene therapy manufacturing will help products reach more patients”, and was written by Akash Bhattacharya, the Senior App…
 
Digital transformations are having wide-ranging and profound impacts within life sciences, creating both opportunities and challenges. One of those challenges is adopting new software systems to drive the transformations. A team from Novartis Institutes of BioMedical Research (NIBR) recognised the need to ensure a good user experience for their in …
 
This is the latest episode of the free DDW podcast, “Paving the way for optimum drug discovery”. It covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 Of DDW and they are read aloud by Megan Thomas. These articles are titled: “In vitro models for assessing drug toxicity: new approaches and development” and “Accelerating as…
 
Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. The company has created some successful partnerships and she explains what these look like, why they have been fruitful, and how they have enabled Twist to use its capabilities to maximum effect. Listen now to hear Math…
 
Aydogdu talks us through how the accurate and quantitative analysis of product purity is a fundamental component of effective development of a biotherapeutic protein. But without consistent techniques and high-quality, reproducible results, it is difficult to precisely assess the product’s efficacy and/or safety, potentially delaying, even jeopardi…
 
Mälarstig is currently responsible for developing and applying strategies for new drug targets and precision medicine. He has extensive experience working in international academic consortia and public–private partnerships such as the SCALLOP consortium. In this podcast he outlines the role of pQTLs in the drug discovery process and the growing imp…
 
The latest episode of the free DDW podcast, “Precision medicine in the era of artificial intelligence”, covers one narrated article of the same title written for DDW and read aloud by Megan Thomas. It was written by Dr Lofti Chouchane and Dr Javaid Sheikh. Dr Chouchane is a professor in the departments of genetic medicine, and microbiology and immu…
 
The latest DDW Sitting Down With podcast features Raj Indupuri, CEO of eClinical Solutions and he talks to us about clinical trials. Listen to find out why Idupuri believes ‘data is the new fuel that will drive human progress’, the effect of Covid-19 on clinical trials and what the sector can learn from the pandemic to make it better prepared for a…
 
This DDW podcast features Dr Hongshan Li, Applications Manager, Sartorius, discussing advances in cell and protein analysis for virology research. This episode examines virology research - what’s currently happening in the sector and how new advances in technology are helping push forward innovation and drug development. With COVID-19 playing such …
 
This narrated article is called “Why flow cytometry in drug discovery is a real life-saver”, in which Roy, Global Product Manager at Miltenyi Biotec, outlines the benefits of flow cytometry, offering case study examples for its use. Capable of boasting high-throughput, accurate, multiparameter and highly reproducible results, it’s time for drug dis…
 
This is the latest episode of the free DDW podcast, titled Vaccine innovation in the age of Covid-19. It covers two narrated articles written for DDW and read aloud by Megan Thomas. These articles are titled: “Vaccine innovation in the age of Covid-19 & beyond” and “Creating vaccines: Why we should be celebrating the life of the researcher”. The fi…
 
This DDW Sitting Down With episode features Guy Goldberg, Chief Business Officer of RedHill Biopharma. In this episode - With vaccines taking centre stage how critical is the part therapeutics have to play in the pandemic? - Goldberg talks us through Covid-19 therapeutics and their role in the pandemic. Goldberg shares his market insight, the benef…
 
Today's episode is titled The potential of metabolomics & COVID-19 Vaccine Development, and covers 2 articles taken from the most recent Fall issue of DDW. These articles are titled: Why metabolomics has the potential to transform diagnosis and treatment. & COVID-19 Vaccine Development: dethroning evil King Coronovirus These articles were firstly b…
 
Today's episode is titled: The power of precision and the potential of human tissue chips, and covers 2 articles taken from the most recent issue of DDW. These articles are titled: The power of precision to keep biologics effective and safe & Why we should be interested in human tissue chips These articles were written by Dr Mark Lies, Global Busin…
 
Today's episode on the topic of The Business Side of Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Building the foundations for post COVID-19 R&D, Opportunity Knocks: Why compound screening libraries are worth the investment, and How to achieve data driven R&D at speed These articles were…
 
Today's episode on the topic of Innovation and Opportunity in Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Japanese drug development: Where is the innovation, Where are the opportunities in global drug discovery, and New for Old: The value behind drug repurposing. These articles were wri…
 
The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in 2030, in particular how the increasing adoption and sophistication of technology will affect companies and patients alike. This article is the second part of a two-part series based on that …
 
This article is the first in a two-part series based on The Pistoia Alliance report. Written in retrospect from the world as it is in 2030, it looks at how healthcare has changed in the intervening decade, covering the socio-economic and political evolutions that have happened, the subsequent effects on population health and the innovative technolo…
 
Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an evidence-based design process that centres on the behaviours and needs of users. The clear benefits of UX offered in the retail and consumer sectors have been slow to percolate to other more complex sectors such as the life s…
 
Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this prevalence is allowed to continue the economic and clinical burden will reach a staggering level. Non-alcoholic fatty liver disease (NAFLD) consists of a complex combination of liver maladies, ranging from…
 
This article will describe, with examples, how understanding the likely mechanisms of false positives in advance of screening informs the design of the hit triage, thus increasing the likelihood of discovering optimisable chemical matter and avoiding costly wasting of resource. We describe the use of a bespoke ‘Robustness Set’ of nuisance compounds…
 
The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission spread and relatively high mortality rates, researchers are under pressure to understand the disease’s pathogenesis, …
 
Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules or biologics becomes increasingly difficult. Cryo-EM empowers drug discovery teams to take advantage of r…
 
In this episode, we discuss the oxymoronic proposition of a Virtual Pharmaceutical Company (VPC) and the typical adopted business model, as well as provide examples of such companies currently trying to undertake this adventurous task. The vagaries and complexities of bringing a therapeutic drug to market through the Drug Discovery and Development …
 
Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This two part article series examines the major initiatives being explored at the public policy level to conta…
 
Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This 2 part episode series examines the major initiatives being explored at the public policy level to contain…
 
The recent outbreak of COVID-19 has highlighted the need for fast and efficient development and production of vaccines for a whole gamut of pathogens, old and new. Microfluidics technologies can be used to accelerate the vaccine development process in a number of ways, not least in the directed evolution of the strains and host organisms used in th…
 
In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically effective antiviral. The aptly named COVID-19 Moonshot aims to accomplish this task more rapid…
 
Live-cell imaging has transformed the study of cell behaviour and function. The technique allows researchers to monitor internal cell structures, interactions and processes in real-time, and over time. In drug discovery, understanding the dynamic processes of cells provides an enhanced picture of drug pharmacology, enabling more reliable prediction…
 
New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking. In pharmacological or genetic perturbation studies using complex biological assays, undesired off-target effects cannot be easily distinguished from the intended mode of action a…
 
This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal... driving stronger biomarker-based insights and decisions and helping to advance new cures and treatment approaches. As we all know, data is increasingly king …
 
The publication of the first human genome sequence more than 15 years ago marked the start of a new era in medicine. In the years since then, researchers have greatly expanded knowledge of gene-disease links and gained a better understanding of the underlying molecular pathways. The first precision therapies, targeted to specific molecular alterati…
 
In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is based on the use of cellular assays and here we debate the advantages and disadvantages of single-cell versus 3D multi-cell analyses. The phenotypic …
 
AI could create a streamlined, automated approach to drug discovery, trawling vast datasets to identify targets, find candidate molecules and predict synthesis routes. Getting there will require significant vision, but we are already seeing exciting examples of AI helping direct research and reduce discovery times. We discuss the short and long ter…
 
Developing and maintaining cell cultures in a stable and sterile environment is of paramount importance to protect samples and increase overall success of drug discovery pipelines. Cell lines are extremely fragile and susceptible to contamination which can be catastrophic in terms of both time and money. Therefore, adequate environmental protection…
 
Bioinformatics has played a major role in gene sequencing diagnostics and has been an essential tool to investigate the genetic causes of disease. With the support of new technologies and tools, bioinformatics can play an important part in the support and continued development of precision medicine. By Mike Furness and John Wise If you'd like to vi…
 
In this episode, we examine the use of 3D organoid cell culture systems as applied to cancer research and the development of novel anti-oncologic drugs. Collectively, this transition from 3D spheroid culture to organoid culture allows researchers to generate multiple organ-specific cell types, resulting in cell architectures that more closely resem…
 
It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent. To capitalise on the microbiome’s potential to improve human health, biotech and pharmaceutical companie…
 
Drug discovery is increasingly informed by genomics, which can significantly boost the chances of a novel therapy successfully navigating the lengthy journey from bench to bedside. But despite the rapid proliferation of genomic information, we still have a limited understanding of how specific genes and genetic variations drive tumour growth and th…
 
Flow cytometry is an invaluable technique for the characterisation of highly heterogeneous cell populations. Thanks to improvements in throughput, automation and multichannel detection capabilities, recent years have seen its use expand across a wide range of drug discovery applications. In this article, we look at novel developments in flow cytome…
 
Despite major investment in the field, few cell therapies have gained regulatory approval with limited commercial success. The success of therapeutic products is defined by three factors: safety, efficacy and scalability. Achieving these for cell therapy presents new challenges; overcoming transplant rejection (and GvHD in the case of immune cells)…
 
Drug discovery teams combine specialists with in-depth knowledge from a variety of scientific disciplines. Such diversity in thought worlds poses a challenging exercise in cross-disciplinary collaboration and project coordination. Based on a longitudinal field study of five projects in a leading pharmaceutical company, we present a framework outlin…
 
In this episode, we look at how commercial products and services are facilitating the automation of cell-based assays to advance drug discovery and accelerate the delivery of new medicines to patients. Cell-based assays are vital tools in modern drug discovery. Live cell cultures that replicate in vivo physiological conditions enable more reliable …
 
New immunotherapies that integrate innate and adaptive immune responses may increase efficacy against many cancers, and have the potential to expand the range of tumours and patients that can be treated with immunotherapy. Over the past decade, insights into the molecular mechanisms that cancer cells use to evade T-cells, antibodies/B cells and oth…
 
In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than that emerging from automated processes. Many common lab procedures now run in parallel, miniaturised experiments – DNA synthesis, target screening, organoid culture, genetic analysis, organic reactions,…
 
Recently there have been attempts by small-to-medium sized pharmaceutical companies to create in-house, integrated platform-DDD (PD3) capabilities. This strategy does not come without risks, but has quietly been implemented to increase drug candidate efficacy/safety and pipeline numbers. In some cases this has resulted in much-vaunted success, as e…
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login